Related Experiment Video
Updated: May 15, 2026

A GMP-Compliant Procedure for the Generation of Gene-Modified T cells
Published on: October 6, 2023
[GammadeltaT cell therapy]
Yoshimasa Tanaka1, Haruki Okamura
1Center for Innovation in Immunoregulative Technology and Therapeutics, Graduate School of Medicine, Kyoto University.
Abstract:
Human gammadeltaT cells recognize pyrophosphomonoesters such as isopentenyl diphosphate and (E)-4-hydroxy-3-methylbut-2 enyl diphosphate derived from microbial pathogens. In addition, they display cytotoxic activity against various tumor cells in an NK receptor-dependent manner. When tumor cells are treated with nitrogen-containing bisphosphonates, gammadeltaT cells exhibit potent anti-tumor activity in a gammadeltaTCR-dependent manner. Based on these findings, gammadeltaT cells have attracted considerable attention in tumor immunotherapy. When gammadeltaT cell frequencies are relatively low, however, it is practically difficult to expand gammadeltaT cells. IL-18 has been recently shown to facilitate the development and proliferation of helper NK cells, which in turn promoted the expansion of gammadeltaT cells. The finding may contribute to the development of novel immunotherapeutic strategies for various cancers.
Insights
Human gammadeltaT cells show promise in cancer immunotherapy by targeting tumor cells. Interleukin-18 (IL-18) aids in expanding these crucial immune cells, offering new therapeutic avenues.
Area of Science:
- Immunology
- Cancer Research
- Cell Biology

